



(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/30 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IB2024/053469

(22) International Filing Date:

09 April 2024 (09.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/495,127 10 April 2023 (10.04.2023) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One MedImmune Way, Gaithersburg, Maryland 20878 (US).(72) Inventors: **MAZOR, Yariv**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **LI, Xiuling**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **PAYNE, Sterling**; ASTRAZENECA PHARMACEUTICALS LP, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437 (US). **WALSENG, Even**; MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **YANG, Chunning**; MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **BRITTON, Zachary**; MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).(74) Agent: **REHFUSS, Patrick M.**; ASTRAZENECA INTELLECTUAL PROPERTY, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(54) Title: OPTIMIZED CD3 ANTIGEN BINDING DOMAINS




Fig. 4

(57) Abstract: The present disclosure relates to antibodies or fragments thereof comprising an antigen binding domain capable of binding to a CDS protein or a fragment thereof. The present disclosure also relates to such antibodies that bind to CDS having optimized affinity to induce T cell activation, but without being associated with excessive cytokine release and reduced tolerability. The disclosure also relates to methods of producing these antibodies and their therapeutic uses.

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE